€100m for biotech firms
While funding is vital, it is no longer the bogey it was in the past when venture capitalists were slow to invest in something they did not understand. In Dublin, last night, it emerged that getting the right management to drive the companies forward once they have done the scientific research was a bigger issue today than money.
Establishing solid commercial alliances with multinationals was another objective regarded as necessary to ensure future growth by companies operating in this dynamic area.
